Reviewing Pacira Pharmaceuticals (PCRX) & Abeona Therapeutics (ABEO)

Pacira Pharmaceuticals (NASDAQ: PCRX) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, earnings, risk and dividends.

Institutional and Insider Ownership

68.6% of Abeona Therapeutics shares are owned by institutional investors. 6.6% of Pacira Pharmaceuticals shares are owned by company insiders. Comparatively, 6.7% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Pacira Pharmaceuticals has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.

Profitability

This table compares Pacira Pharmaceuticals and Abeona Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pacira Pharmaceuticals -11.45% -5.81% -2.56%
Abeona Therapeutics -939.83% -23.57% -22.34%

Analyst Recommendations

This is a summary of current ratings and target prices for Pacira Pharmaceuticals and Abeona Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pacira Pharmaceuticals 1 11 9 0 2.38
Abeona Therapeutics 0 0 8 0 3.00

Pacira Pharmaceuticals presently has a consensus target price of $45.18, suggesting a potential upside of 29.45%. Abeona Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 58.98%. Given Abeona Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than Pacira Pharmaceuticals.

Earnings and Valuation

This table compares Pacira Pharmaceuticals and Abeona Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pacira Pharmaceuticals $286.63 million 4.96 -$42.61 million ($0.58) -60.17
Abeona Therapeutics $840,000.00 1,062.79 -$27.31 million ($0.66) -28.59

Abeona Therapeutics has lower revenue, but higher earnings than Pacira Pharmaceuticals. Pacira Pharmaceuticals is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Pacira Pharmaceuticals beats Abeona Therapeutics on 7 of the 13 factors compared between the two stocks.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

About Abeona Therapeutics

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply